Literature DB >> 9206226

[The changes of hemodynamics in ocular trauma and treatment with compound anisodine].

Y Zhu1, C Song, S Wang.   

Abstract

OBJECTIVE: To study the changes of hemodynamics in human ocular trauma and treatment with compound anisodine.
METHODS: 34 cases with ocular trauma were examined by rheoophthalmography (ROG) and Doppler ultrasonography (DUSG).
RESULTS: It appeared that the wave amplitudes of ROG were lower in both injured and contralateral eyes, which indicated the ocular blood flow was reduced. The speed of systolic blood flow in ophthalmic artery (OA), the value of systolic peak frequency (PK) in internal carotid artery (ICA) and common carotid artery (CCA) in DUSG were increased, indicating that there were certain degrees of blood vessel spasm in OA, ICA and CCA.
CONCLUSION: Ocular trauma not only directly impairs the vasomotor function of injured eyes but also affects the vasomotor function of contralateral eyes and the function of the autonomic nervous system or cerebral cortex by consensual reaction. The treatment by compound anisodine may effectively relieve and restore the above changes and improve the visual function. ROG and DUSG are sensitive and objective to estimate the changes of hemodynamics and evaluate the therapeutic effect in ocular trauma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9206226

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  2 in total

1.  Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion.

Authors:  Xiao-Jun Wu; Feng Gao; Xu Liu; Qing Zhao
Journal:  Exp Ther Med       Date:  2016-09-07       Impact factor: 2.447

2.  Compound anisodine affects the proliferation and calcium overload of hypoxia-induced rat retinal progenitor cells and brain neural stem cells via the p-ERK1/2/HIF-1α/VEGF pathway.

Authors:  Qun Wang; Shan Gao; Yu Luo; Qian-Yan Kang
Journal:  Exp Ther Med       Date:  2017-05-31       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.